INKT

MiNK Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About INKT

Mink Therapeutics, Inc.

A biotechnology company focused on developing cancer immunotherapies and autoimmune disease treatments

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

10/15/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.minktherapeutics.com

Security Type

Common stock

Office address

149 Fifth Avenue, Suite 500, New York, NY 10010

Business

Introduction

MiNK Therapeutics, Inc., was incorporated in Delaware in July 2017. The Company is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf iNKT cell therapies for the treatment of cancer and other immune-mediated diseases. The company is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of natural and engineered iNKT cells with multiple clinical and preclinical readouts expected in 2021 and 2022. The company's strategy is to advance an accessible, scalable and effective cell therapy platform that leverages the innate and durable biological advantages of iNKT cells to optimize scalability and rapid clinical development.

Company Financials

EPS

INKT has released its 2024 Q4 earnings. EPS was reported at -0.62, versus the expected -0.50, missing expectations. The chart below visualizes how INKT has performed over recent quarters, highlighting trends in earnings surprises.